sapacitabine Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Sapacitabine is a chemotherapeutic drug developed by US biotechnology firm Cyclacel currently undergoing clinical trials against leukemia.   Wikipedia

Chemistry

  • SMILES: CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N
  • InChIKey: LBGFKUUHOPIEMA-PEARBKPGSA-N
  • Mol. Mass: 490.65
  • ALogP: 4.05
  • ChEMBL Molecule:
    sapacitabine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

2'-c-cyano-2'-deoxy-1-arabinofuranosyl-n(4)-palmitoylcytosine | cndac cpd | cs-682 | cyc682 | cyc 682 | cyc-682 | sapacitabine

Organizations (9)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Breast Neoplasms (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Ischemic Stroke (Phase 1)

Leukemia (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma, T-Cell (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue